Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes

The antihyperglycemic agent linagliptin, a dipeptidyl peptidase-4 (DPP-IV) inhibitor, has been shown to reduce inflammation and improve endothelial cell function. In this study, we hypothesized that DPP-IV inhibition with linagliptin would improve impaired cerebral perfusion in diabetic rats, as wel...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Am J Physiol Regul Integr Comp Physiol
Main Authors: Hardigan, Trevor, Yasir, Abdul, Abdelsaid, Mohammed, Coucha, Maha, El-Shaffey, Sally, Li, Weiguo, Johnson, Maribeth H., Ergul, Adviye
Format: Artigo
Jezik:Inglês
Izdano: American Physiological Society 2016
Teme:
Obesity, Diabetes and Energy Homeostasis
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5142225/
https://ncbi.nlm.nih.gov/pubmed/27357799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajpregu.00057.2016
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki